226 results about "Tetrahydrothiophene" patented technology

There are provided a liquid crystalline compound having a large negative Deltaepsilon, low viscosity, a large K33 / K11 value, a small Deltaepsilon / epsilonL and mutually excellent solubility even at extremely low temperature; a liquid crystal composition prepared from a liquid crystalline compound; and a liquid crystal display device fabricated from such a liquid crystal composition. The liquid crystalline compound of the present invention is a liquid crystalline compound represented by the following general formula (1): where, R<1 >represents hydrogen, fluorine, an alkyl group having 1 to 15 carbon atoms, or an alkenyl group having 2 to 15 carbon atoms; each of rings A<1>, A<2>, and A<3 >independently represents trans-1,4-cyclohexylene group, 1,4-cyclohexenylene group, trans-1,4-silacyclohexylene group, 1,4-phenylenegroup, 2,3-difluoro-1,4-phenylene group, 2-fluoro-1,4-phenylene group, 3-fluoro-1,4-phenylene group, pyrimidine-2,5-diyl group, pyridine-2,5-diyl group, 1,3-dioxane-2,5-diyl group, tetrahydropyrane-2,5-diyl group, 1,3-dithiane-2,5-diyl group, or tetrahydrothiopyrane-2,5-diyl group; X<1 >represents hydrogen or fluorine; Y<1 >represents hydrogen or an alkyl group having 1 to 15 carbon atoms; 1 represents an integer from 1 to 10; and each of m and n independently represents 0 or 1.

A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.

The invention relates to hydrogenated pyridine derivates of 2-acetoxy-5-(Alpha-cyclopropyl carbonyl-2-fluorobenzyl)-4, 5, 6, 7-tetrahydrothiophene-[3, 2-C] pyridine as well as a preparation method of salt thereof. The method is to prepare two key intermediates of an Alpha-cyclopropyl carbonyl-2-fluorobenzyl halogen 2 (wherein, X=F, CL, Br and I) and a 2-oxygen-2, 4, 5, 6, 7, 7 Alpha-hexahydrothiophene-[3, 2-C] pyridine salt 3 (wherein, HA=HCL, H2SO4, HBr, HI, etc.), and to obtain the target product by esterifying products acquired through condensing the two key intermediates with acetic anhydride. The target product and the required acid addition salt are added with the needed crystal seed for obtaining crystals with a single crystal form in the process of crystallization.